University of Vermont

College of Medicine

Department of Neurological Sciences

Bio for Robert Shapiro, M.D., Ph.D.
Robert Shapiro, M.D., Ph.D.

Robert Shapiro, M.D., Ph.D.

Department of Neurological Sciences

Contact Information
Clinic (802) 847-4589
Office Location:
Department of Neurology, 1 South Prospect St. - Arnold 2435D, Burlington, VT 05401


1987:  Columbia University, New York, NY. Doctor of Medicine.
1985:  University of Oxford, Oxford, England. Master of Arts in Philosophy/Psychology.
1984:  University of Pennsylvania, Philadelphia, PA. PhD in Anatomy.
1980:  University of Oxford, Oxford, England. Bachelor of Arts in Philosophy/Psychology with honors.
1978:  University of Pennsylvania, Philadelphia, PA. Master of Arts in Biology.
1978:  University of Pennsylvania, Philadelphia, PA. Bachelor of Arts in Biology. cum laude.

Awards and Honors

2013: American Academy of Neurology, Kenneth M. Viste, Jr., MD, Patient Advocate of the Year Award
2013: Headache Cooperative of New England, Lifetime Achievement ('Megrim') Award
2013: Fellow, American Academy of Neurology
2012: American Headache Society, Harold G. Wolff Lecture Award
2008-2012: Founding President, Alliance For Headache Disorders Advocacy
2007: American Academy of Neurology, Palatucci Advocate of the Year Award
2003-2005:  Frymoyer Scholar, College of Medicine, University of Vermont
2002-2008: President, Headache Cooperative of New England
2002:  Migraine Innovators Merit Award, AstraZeneca Pharmaceuticals  
1996:  Solo Cup Clinician Scientist Award, Johns Hopkins School of Medicine  
1991-1996:  NIH / NINDS [K08], Clinical Investigator Development Award
1991:  Merck Clinician Scientist Award, Johns Hopkins School of Medicine 
1987:  The Helen M. Sciarra Prize in Neurology, Columbia University 
1980-1981: University Fellowship, University of Pennsylvania
1978-1980:  Thouron Award, University of Oxford, England    


Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y, Lee HY, Jones CR, Fu YH, Charles AC, Ptácek LJ. Casein kinase id mutations in familial migraine and advanced sleep phase. Sci Transl Med. 5:183ra56 (2013).

Shapiro RE. Lagniappe: the impact of headache disorders in America. Headache. 53:196-204 (2013).

Schürks, M., P.M. Rist, R.E. Shapiro, T. Kurth. Migraine and Mortality: A systematic review and meta-analysis. Cephalalgia. 31:1301-14 (2011).

Evans, R.W., S.J. Tepper, R.E. Shapiro, C. Sun-Edelstein, & G.E. Tietjen. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society Position Paper Headache 50:1089-1099 (2010).

Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970-7 (2009).

Xu Y, Padiath QS, Shapiro RE, Jones CR, Wu SC, Saigoh N, Saigoh K, Ptácek LJ, Fu YH. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 434:640-4 (2005).

Paznekas WA, Boyadjiev SA, Shapiro RE, Daniels O, Wollnik B, Keegan CE, Innis JW, Dinulos MB, Christian C, Hannibal MC, Jabs EW. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am J Hum Genet. 72:408-18. (2003).

To view more of Dr. Shapiro's publications, please visit PubMed.